Industry Partnerships
Removing barriers to accelerate the development of visionary therapies
// Partnering
What We Do
We cultivate thriving partnerships that break new ground for cell and gene therapies. Our partnerships include early-stage private companies to large market cap public companies, with programs at varying stages of development and commercialization. With our end-to-end capabilities, partnering with us provides the best potential for success by centralizing your work.
ElevateBio can act as a guide on your expedition, offering the resources and expertise needed to make your journey faster and smoother. We can increase efficiencies and lower costs to find the best path to bring your concepts from bench to bedside. Our technology-forward approach allows us to provide our partners with next-generation technologies and a team of experts with decades of experience in cell and gene therapy innovation.
Our Partnership Spotlights
Developing Base Editing Therapies in a Multi-Target Collaboration with Novo Nordisk
Life Edit Therapeutics, an ElevateBio company, formed a strategic collaboration with Novo Nordisk to discover, develop, and deliver base editing therapies for rare and cardiometabolic diseases. Novo Nordisk will leverage Life Edit’s suite of gene editing technologies to precisely edit the genome with the aim of developing life-changing therapies.
Accelerating the Development of Novel In Vivo Gene Editing Therapies with Moderna Therapeutics
Life Edit Therapeutics, an ElevateBio company, formed an R&D collaboration with Moderna Therapeutics to discover and develop in vivo mRNA gene editing therapies, combining the platform technologies of both organizations.
Advancing the Discovery and Development of Regenerative Medicine with CIRM
ElevateBio partnered with the California Institute for Regenerative Medicine (CIRM) to develop iPSC-derived therapeutics. Through the collaboration, we are providing academic institutions and biopharmaceutical companies access to our integrated ecosystem of iPSC lines, vector technology, process development and manufacturing capabilities to accelerate the discovery and development of cell and gene therapies.
Integrating our LentiPeak™ Lentiviral Vector Platform into Affini-T’s Clinical Development
ElevateBio partnered with Affini-T Therapeutics to advance Affini-T’s engineered TCR-T therapies into clinical development leveraging our LentiPeak™ lentiviral vector technology platform and cell therapy production capabilities.
Partner Testimonials
Deep expertise in autologous cellular therapies manufacturing and analytics combined with its scalable platform for suspension-based lentiviral production, make ElevateBio an ideal partner as we progress our oncogenic driver programs into the clinic and work to deliver transformative therapies to patients and their families.
Collaboration with ElevateBio [lets us] outsource all MFG, and [we] are able to leverage [their] cell bio expertise. Their strategy was capital efficient and saved time: 6 months after launch had baseline MFG process that took ~1 year off IND.
Partner With Us
Wherever you are in your product lifecycle, we can strengthen and accelerate the development of your transformative therapies with our enabling technologies unmatched manufacturing capabilities.
// Work with us
